Agios Pharmaceuticals Inc

2026. g. 24. aug. 19:36 UTC

Agios Pharmaceuticals Inc shares are lower today, continuing a decline since Friday's close amid broader market volatility linked to geopolitical events.

2026. g. 21. aug. 19:36 UTC

Agios Pharmaceuticals Inc shares are lower during Friday's session amid rising U.S. Treasury yields and ongoing geopolitical tensions. No specific news was identified.

2026. g. 20. aug. 20:01 UTC

Agios Pharmaceuticals Inc. shares are lower today, driven by a significant downturn in the Biotechnology sector and heightened trading volume.

2026. g. 19. aug. 20:06 UTC

Agios Pharmaceuticals shares are higher today, though they pulled back from a session high. Broader market sentiment may be influenced by rising cryptocurrency values.

2026. g. 18. aug. 22:51 UTC

Agios Pharmaceuticals shares are lower in after-market hours, amid broader negative sentiment linked to rising sovereign bond yields and persistent inflation risks.

2026. g. 17. aug. 19:41 UTC

Agios Pharmaceuticals shares are rising as Cantor Fitzgerald maintains an Overweight rating ahead of the November 1 PDUFA date for mitapivat.

2026. g. 14. aug. 19:46 UTC

Agios Pharmaceuticals Inc shares are higher today, though no specific news explains the movement. Earlier, shares peaked before dipping later in the session.

2026. g. 12. aug. 20:01 UTC

Agios Pharmaceuticals Inc shares are higher today amid unusually high trading volume. The stock has gained significantly since Tuesday's close.

2026. g. 11. aug. 19:26 UTC

Agios Pharmaceuticals Inc shares are higher today, with no specific news driving the move. Market focus remains on upcoming U.S. inflation reports.

2026. g. 10. aug. 21:01 UTC

Agios Pharmaceuticals Inc shares are lower in after-market trading, with no specific news identified to explain the decline. The stock remains below its 20-day moving average.

2026. g. 6. aug. 19:32 UTC

Agios Pharmaceuticals shares are higher today, continuing an upward trend since Wednesday. The stock peaked earlier in the session before a slight pullback.

2026. g. 5. aug. 19:56 UTC

Agios Pharmaceuticals is under investigation regarding its decision on tebapivat, contributing to lower trading activity today amid ongoing investor concerns.

2026. g. 4. aug. 20:02 UTC

Agios Pharmaceuticals Inc shares are higher today amid broader market gains, supported by falling crude oil prices and comments on potential peace talks with Iran.

2026. g. 3. aug. 20:06 UTC

Agios Pharmaceuticals Inc shares are higher today, continuing an upward trend since Friday's close. No specific news was identified to explain the movement.

2026. g. 31. jūl. 22:51 UTC

Agios Pharmaceuticals Inc. shares are lower in after-market hours, reflecting broader market declines amid mixed tech earnings and rising U.S. Treasury yields.

2026. g. 30. jūl. 20:08 UTC

Agios Pharmaceuticals shares are lower today amid mixed economic signals and unusually high trading volume. The stock has declined since Wednesday's close.

2026. g. 29. jūl. 20:51 UTC

Agios Pharmaceuticals Inc shares gained in after-market trading, rebounding from a session low despite broader market pressures from rising crude oil prices and geopolitical tensions.

2026. g. 28. jūl. 20:02 UTC

Agios Pharmaceuticals shares are lower amid an investigation into potential claims following the halted development of tebapivat for sickle cell disease.

2026. g. 27. jūl. 20:01 UTC

Agios Pharmaceuticals Inc shares are higher during Monday's session, reaching a notable peak earlier in the day. No specific news was identified for the move.

2026. g. 24. jūl. 23:21 UTC

Agios Pharmaceuticals shares are higher in after-market trading, supported by a decline in initial jobless claims, indicating a robust labor market.

2026. g. 22. jūl. 22:41 UTC

Agios Pharmaceuticals shares are lower in after-market trading, continuing a three-session decline amid broader market concerns over rising crude oil prices and inflation.

2026. g. 21. jūl. 19:01 UTC

Agios Pharmaceuticals shares declined after discontinuing tebapivat development for sickle cell disease, despite some trial improvements. The stock remains lower since Monday's close.